Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma

被引：6

作者：

Hirai, Noriko ^{[1
]}

Sasaki, Takaaki ^{[1
]}

Okumura, Shunsuke ^{[1
]}

Sado, Masatoshi ^{[2
]}

Akiyama, Naoko ^{[2
]}

Kitada, Masahiro ^{[1
,3
]}

Takei, Hidehiro ^{[2
]}

Ohsaki, Yoshinobu ^{[1
]}

机构：

[1] Asahikawa Med Univ, Resp Ctr, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan

[2] Asahikawa Med Univ, Dept Pathol, Asahikawa, Hokkaido, Japan

[3] Asahikawa Med Univ, Breast Dis Ctr, Asahikawa, Hokkaido, Japan

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 02期

关键词：

Anaplastic lymphoma receptor tyrosine kinase (ALK); mRNA in situ hybridization (mRNA-ISH); fluorescence in situ hybridization (FISH); immunohistochemistry (IHC); lung adenocarcinoma; MOLECULAR TESTING GUIDELINE; KINASE INHIBITORS GUIDELINE; OF-AMERICAN-PATHOLOGISTS; INTERNATIONAL-ASSOCIATION; CANCER PATIENTS; CRIZOTINIB; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMAS; CLASSIFICATION; REARRANGEMENT;

D O I：

10.21037/tlcr.2020.03.04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A recent technical advance in mRNA in situ hybridization (mRNA-ISH) assays provides simultaneous signal amplification and background suppression with a unique probe design that enables single-molecule visualization. We assessed the utility of the mRNA-ISH assay as a diagnostic tool for detecting anaplastic lymphoma receptor tyrosine kinase (ALK) mRNA in non-small-cell lung carcinoma (NSCLC). We compared the mRNA-ISH assay with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Methods: The study included 279 surgically resected lung adenocarcinomas and 44 transbronchial-biopsied (TBB) adenocarcinomas. mRNA-ISH was conducted using the RNAscope 2.0 system, which includes pre-designed probes for detecting the tyrosine kinase domain encoded in ALK mRNA. IHC was conducted on all 323 samples using ALK-specific antibodies. mRNA-ISH was performed on 279 surgical samples and 6 TBB samples. Break-apart FISH was used to examine samples that were mRNA-ISH-positive or IHC-positive. Results: ALK protein expression was detected in 11 of 279 specimens (3.9%). ALK mRNA was also detected with mRNA-ISH in ALK-positive samples, and 9 of the 11 specimens (81%) were also positive for ALK using break-apart FISH. Using the IHC results as a reference, the sensitivity and specificity of mRNA-ISH was 100%. In the TBB cohort, ALK protein expression was observed in 3 of 44 specimens (6.8%), in which ALK mRNA expression was also detected. Conclusions: The ALK mRNA-ISH data were highly correlated with the IHC data, and ALK mRNA-ISH detected ALK mRNA expression in every FISH-positive sample. We conclude that mRNA-ISH could serve as an alternative or complementary method for diagnosing ALK rearrangements in NSCLC.

引用

页码：257 / 268

页数：12

共 21 条

[1]

[Anonymous], 2013, IASLC ATLAS ALK TEST

[2]

Brierley J., 2016, TNM CLASSIFICATION M

[3] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[4] Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent [J].

Conklin, Chris M. J. ;

Craddock, Kenneth J. ;

Have, Cherry ;

Laskin, Janessa ;

Couture, Christian ;

Ionescu, Diana N. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :45-51

[5] Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches [J].

Drilon, Alexander ;

Wang, Lu ;

Arcila, Maria E. ;

Balasubramanian, Sohail ;

Greenbowe, Joel R. ;

Ross, Jeffrey S. ;

Stephens, Phil ;

Lipson, Doron ;

Miller, Vincent A. ;

Kris, Mark G. ;

Ladanyi, Marc ;

Rizvi, Naiyer A. .

CLINICAL CANCER RESEARCH, 2015, 21 (16) :3631-3639

[6] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial [J].

Hida, Toyoaki ;

Nokihara, Hiroshi ;

Kondo, Masashi ;

Kim, Young Hak ;

Azuma, Koichi ;

Seto, Takashi ;

Takiguchi, Yuichi ;

Nishio, Makoto ;

Yoshioka, Hiroshige ;

Imamura, Fumio ;

Hotta, Katsuyuki ;

Watanabe, Satoshi ;

Goto, Koichi ;

Satouchi, Miyako ;

Kozuki, Toshiyuki ;

Shukuya, Takehito ;

Nakagawa, Kazuhiko ;

Mitsudomi, Tetsuya ;

Yamamoto, Nobuyuki ;

Asakawa, Takashi ;

Asabe, Ryoichi ;

Tanaka, Tomohiro ;

Tamura, Tomohide .

LANCET, 2017, 390 (10089) :29-39

[7] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].

Kwak, Eunice L. ;

Bang, Yung-Jue ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Solomon, Benjamin ;

Maki, Robert G. ;

Ou, Sai-Hong I. ;

Dezube, Bruce J. ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Varella-Garcia, Marileila ;

Kim, Woo-Ho ;

Lynch, Thomas J. ;

Fidias, Panos ;

Stubbs, Hannah ;

Engelman, Jeffrey A. ;

Sequist, Lecia V. ;

Tan, WeiWei ;

Gandhi, Leena ;

Mino-Kenudson, Mari ;

Wei, Greg C. ;

Shreeve, S. Martin ;

Ratain, Mark J. ;

Settleman, Jeffrey ;

Christensen, James G. ;

Haber, Daniel A. ;

Wilner, Keith ;

Salgia, Ravi ;

Shapiro, Geoffrey I. ;

Clark, Jeffrey W. ;

Iafrate, A. John .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703

[8] Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [J].

Lindeman, Neal I. ;

Cagle, Philip T. ;

Aisner, Dara L. ;

Arcila, Maria E. ;

Beasley, Mary Beth ;

Bernicker, Eric H. ;

Colasacco, Carol ;

Dacic, Sanja ;

Hirsch, Fred R. ;

Kerr, Keith ;

Kwiatkowski, David J. ;

Ladanyi, Marc ;

Nowak, Jan A. ;

Sholl, Lynette ;

Temple-Smolkin, Robyn ;

Solomon, Benjamin ;

Souter, Lesley H. ;

Thunnissen, Erik ;

Tsao, Ming S. ;

Ventura, Christina B. ;

Wynes, Murry W. ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) :323-358

[9] Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [J].

Lindeman, Neal I. ;

Cagle, Philip T. ;

Beasley, Mary Beth ;

Chitale, Dhananjay Arun ;

Dacic, Sanja ;

Giaccone, Giuseppe ;

Jenkins, Robert Brian ;

Kwiatkowski, David J. ;

Saldivar, Juan-Sebastian ;

Squire, Jeremy ;

Thunnissen, Erik ;

Ladanyi, Marc .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (04) :415-453

[10] A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry [J].

Mino-Kenudson, Mari ;

Chirieac, Lucian R. ;

Law, Kenny ;

Hornick, Jason L. ;

Lindeman, Neal ;

Mark, Eugene J. ;

Cohen, David W. ;

Johnson, Bruce E. ;

Jaenne, Pasi A. ;

Iafrate, A. John ;

Rodig, Scott J. .

CLINICAL CANCER RESEARCH, 2010, 16 (05) :1561-1571

← 1 2 3 →